Biotech

Sanofi picks brand new CSO coming from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is coming back to the pharma crease, taking up the leading science area at Sanofi.Quigley will start Sept. 30 as the French Big Pharma's main medical police officer as well as international director of research study, Sanofi told Ferocious Biotech in an emailed statement.Quigley is substituting Frank Nestle, M.D., who left behind Sanofi this spring among a global overhaul of the company's R&ampD system. Nestle, that spent 8 years along with the pharma, leapt over to Deerfield Management, where he currently functions as a partner on the therapeutics staff and also chief executive officer of the company's healing discovery and progression operations.
Quigley will definitely sign up with Sanofi coming from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn profile. He's presently detailed as the company's co-founder, head of state and also CEO.Since August 2021, Quigley has actually acted as a project partner at SV Health Investors, a healthcare fund manager along with present expenditures in biotechs such as BioAge, Cerevance, Dualitas Therapeutics and Nimbus Rehabs, among others. Quigley in the past kept the best area at Dualitas, a biotech that continues to be in secrecy, according to STAT.The future Sanofi leader additionally earlier helmed Therini Bio, an immunotherapy biotech functioning to build therapies for neurodegenerative conditions steered by vascular disorder.Before spending the last handful of years in biotech, Quigley has an even longer record in Major Pharma, very most lately acting as Gilead's elderly bad habit president of research study the field of biology up until the summer of 2021. Before that, he clocked in more than 4 years across numerous leadership parts at Bristol Myers Squibb as well as functioned as a medical director at Johnson &amp Johnson's Janssen arm prior to that.Sanofi pointed out Quigley's goal in his brand new role would be actually to "maximize our likelihood of excellence through optimum collaborations throughout our institution and past, carrying best-in-class technology along with establishing and also sourcing brand new industry-leading talent along with a devotion to variety," according to an internal memo obtained through STAT.